Literature DB >> 31943341

CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.

Jorge J Castillo1,2, Joshua N Gustine1,3, Kirsten Meid1, Catherine A Flynn1, Maria G Demos1, Maria L Guerrera1, Cristina Jimenez1, Amanda Kofides1, Xia Liu1, Manit Munshi1, Nicholas Tsakmaklis1, Christopher J Patterson1, Lian Xu1, Guang Yang1,2, Zachary R Hunter1,2, Steven P Treon1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31943341     DOI： 10.1002/ajh.25730

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

Review 1.  Management of Waldenström macroglobulinemia in 2020.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up.

Authors:  Jorge J Castillo; Kirsten Meid; Catherine A Flynn; Jiaji Chen; Maria G Demos; Maria L Guerrera; Amanda Kofides; Xia Liu; Manit Munshi; Nicholas Tsakmaklis; Christopher J Patterson; Guang Yang; Zachary Hunter; Steven P Treon
Journal:  Blood Adv       Date:  2020-08-25

3.  Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.

Authors:  Marie José Kersten; Karima Amaador; Monique C Minnema; Josephine M I Vos; Kazem Nasserinejad; Marcel Kap; Efstathios Kastritis; Maria Gavriatopoulou; Willem Kraan; Martine E D Chamuleau; Dries Deeren; Lidwine W Tick; Jeanette K Doorduijn; Fritz Offner; Lara H Böhmer; Roberto D Liu; Steven T Pals; Meletios A Dimopoulos
Journal:  J Clin Oncol       Date:  2021-08-13       Impact factor: 44.544
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.